TY - JOUR
T1 - Tumor angiogenesis—characteristics of tumor endothelial cells
AU - Hida, Kyoko
AU - Maishi, Nako
AU - Torii, Chisaho
AU - Hida, Yasuhiro
N1 - Publisher Copyright:
© 2016, Japan Society of Clinical Oncology.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Tumor blood vessels provide nutrition and oxygen to the tumor, resulting in tumor progression. They also act as gatekeepers, inducing tumor metastasis. Thus, targeting tumor blood vessels is an important strategy in cancer therapy. Tumor endothelial cells (TECs), which line the inner layer of blood vessels of the tumor stromal tissue, are the main targets of anti-angiogenic therapy. Because new tumor blood vessels generally sprout from pre-existing vasculature, they have been considered to be the same as normal blood vessels. However, tumor blood vessels demonstrate a markedly abnormal phenotype that includes several important morphological changes. The degree of angiogenesis is determined by the balance between the angiogenic stimulators and inhibitors released by the tumor and host cells. Recent studies have revealed that TECs also exhibit altered characteristics which depend on the tumor microenvironment. Here, we review recent studies on TEC abnormalities and heterogeneity with respect to tumor progression and consider their therapeutic implications.
AB - Tumor blood vessels provide nutrition and oxygen to the tumor, resulting in tumor progression. They also act as gatekeepers, inducing tumor metastasis. Thus, targeting tumor blood vessels is an important strategy in cancer therapy. Tumor endothelial cells (TECs), which line the inner layer of blood vessels of the tumor stromal tissue, are the main targets of anti-angiogenic therapy. Because new tumor blood vessels generally sprout from pre-existing vasculature, they have been considered to be the same as normal blood vessels. However, tumor blood vessels demonstrate a markedly abnormal phenotype that includes several important morphological changes. The degree of angiogenesis is determined by the balance between the angiogenic stimulators and inhibitors released by the tumor and host cells. Recent studies have revealed that TECs also exhibit altered characteristics which depend on the tumor microenvironment. Here, we review recent studies on TEC abnormalities and heterogeneity with respect to tumor progression and consider their therapeutic implications.
UR - http://www.scopus.com/inward/record.url?scp=84958039295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958039295&partnerID=8YFLogxK
U2 - 10.1007/s10147-016-0957-1
DO - 10.1007/s10147-016-0957-1
M3 - Review article
C2 - 26879652
AN - SCOPUS:84958039295
SN - 1341-9625
VL - 21
SP - 206
EP - 212
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 2
ER -